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A short-term antihypertensive treatment-induced fall in
glomerular filtration rate predicts long-term stability of
renal function
ALFRED J. APPERLOO, DICK DE ZEEUW, and PAUL E. DE JUNG
Department of Medicine, Division of Nephrology, University Hospital Groningen, Groningen, The Netherlands
A short-term antihypertensive treatment-induced fall in glomerular
filtration rate predicts long-term stability of renal function. In long-term
intervention studies on renal function outcome an initial decline in the
glomerular filtration rate (GFR) may occur after starting therapy. If this
initial GFR decline is the result of a treatment-induced hemodynamic
change reflecting a fall in intraglomerular pressure, it should be reversible
after treatment withdrawal, even after long-term treatment. In fact, it
could be beneficial for renal function in the long term. We therefore
studied systemic and renal hemodynamics in 40 non-diabetic patients with
impaired renal function before treatment, during four years treatment
with either atenolol or enalapril, and after withdrawal of that treatment.
The acute change in GFR 12 weeks after start of treatment varied widely
from —11 to +11 ml/min (mean SD —1.0 4.1 ml/min, NS). After four
years of treatment, withdrawal for 12 weeks resulted in a rise in GFR of
+2.2 5.4 mI/mm, P = 0.011, again with a wide range of +14 to —6
mI/mm). The initial fall in GFR was related to the rise after withdrawal
(r = 0.32,P < 0.05). Interestingly, the acute treatment induced change in
GFR correlated with the long-term slope, such that a patient with a
greater initial decline in GFR showed a more stable course during the
follow up (r = —0.36, P < 0.05). The patients were arbitrarily divided in
group A (N = 20), with the largest initial treatment-induced fall in GFR,
and group B (N = 20), with the smallest initial fall in GFR. Group A had
a significantly less steep slope than group B (—0.41 1.52 vs. —2.09
2.79 mI/mm/year, P = 0.023) during the four year follow-up. In group A
GFR increased again after withdrawal of treatment (+3.8 5.6 mI/mm,
P = 0.011) whereas it did not change in group B (+0.5 4.0 mI/mm, NS).
As a consequence, GFR post-treatment was not different compared to
pre-treatment in group A (—2.5 7.2 ml/min, NS), whereas it was 5.9
12.1 mI/mm lower in group B (P = 0.023). Patients treated with enalapril
had a similar response as patients treated with atenolol. In conclusion, an
initial fall in GFR after starting antihypertensive treatment in patients
with a mild to moderate renal function impairment (GFR 30 to 90 mI/mm)
is reversible even after years of treatment, suggesting that this therapy-
induced fall is of hemodynamic and not of structural origin. This initial
GFR fall was associated with a subsequent stable renal function. These
data lead to the hypothesis that the initial fall in GFR in response to
antihypertensive therapy reflects renal protection.
It is well known that adequate antihypertensive treatment may
improve long-term renal function outcome [1, 21. On the other
hand, during the initial months of antihypertensive treatment
renal function in some patients may fall considerably [3—5]. This
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may be bothersome, particularly in patients with impaired renal
function, in volume depleted patients and in patients who are
instituted on an ACE inhibitor [3]. As such, this initial fall in
glomerular filtration rate (GFR) may be designated as an un-
wanted effect of antihypertensive treatment. However, this de-
cline in GFR may well reflect a lowering of intraglomerular
pressure. If so, the fall in GFR should be reversible after
withdrawal of the treatment, even after a long time. In addition,
since raised intraglomerular pressure has been associated with
progressive renal function loss [6], an initial fall in GFR could
predict the effectiveness of the therapy to prevent renal function
deterioration during long term treatment. This would also impli-
cate that common recommendations advocating discontinuation
of antihypertensive treatment when an initial decline in GFR
occurs, could be misleading. To address this issue, we prospec-
tively studied the renal hemodynamic response in 40 non-diabetic
patients with varying degrees of renal function impairment before
treatment, during four years treatment with either atenolol or
enalapril, and after withdrawal of that treatment.
Methods
Patients and protocol
Before study entry the patients had to fulfill the following
criteria: a baseline creatinine clearance between 30 and 90
ml/min, a pre-treatment diastolic blood pressure > 80 mm Hg
and < 110 mm Hg, and no contra-indications for treatment with
either a beta blocking agent or an angiotensin I converting
enzyme inhibitor. The study was approved by the local Medical
Ethical Committee. Dietary restrictions in the study followed the
routine policy of the nephrology out-patient clinic. All patients
adhered to a sodium restricted diet (50 to 80 mmol sodium per
day). Protein intake was 0.8 to 1,0 g/kg body wt in the patients with
a creatinine clearance of 60 to 90 mI/mm, and 0.6 to 0.8 g/kg body
wt in those with a creatinine clearance of 30 to 60 mI/mm. All
antihypertensivcs were withdrawn at least three weeks before
active treatment started. In the pre-treatment period the patients
were seen every one to two weeks. Thereafter, patients were
randomized to receive either enalapril 10 mg per day or atenolol
50 mg per day in a double blind fashion. The goal of treatment was
to lower diastolic blood pressure to less than 95 mm Hg and by
more than 10 mm Hg. Patients were seen every four weeks during
the subsequent twelve week titration period. If the target blood
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Table 1. Course of the study parameters in the 40 patients at baseline, during treatment and after treatment withdrawal
.Baseline
week 0
Long-term treatment Recovery
week 216week 12 week 204
SBP mm Hg
DB mm Hg
154.3 21.9
91.1 12.7
130.5 15.SC
76.2 9.2C
133.9 16.9a
76.4 95C
158.2 22•3hc
91.5 13.2
MAP mm Hg 112.1 14.5 94•3 99C 95.6 hOC 113.7 15.11c
GFR mI/mm 55.9 22.4 54.9 23.5 49.5 23.9' 51.7 25.5
ERPF mI/mm 213.4 82.3 223.7 87.2' 192.7 83.0' 190.0 93.7°'
FF 0.266 0.043 0.248 0.046 0.257 0.045 0.276 0.045c
Protg/day 0.91 1.59 0.53 1.16 0.72 1.38 1.52 ÷ 206hc
Abbreviations are: SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; GFR, glomerular filtration rate; ERPF,
effective renal plasma flow; FF, filtration fraction; Prot, proteinuria.
Significance is indicated by compared to week 0, b compared to week 12, and by C compared to week 204.
pressure was not reached, the dose of the antihypertensive drug
could be increased stepwise to either 40 mg enalapril or 100 mg
atenolol per day. Additionally, hydrochlorothiazide could be
added in a dose of 25 or 50 mg per day. Then if the blood pressure
goal was still not reached, either a calcium entry blocker or
clonidine could be added in the titration period. Patients requir-
ing a diuretic and or a calcium entry blocker/clonidine were not
removed from the study. If hypotensive symptoms occurred the
dose was lowered to 5 mg enalapril or 25 mg atenolol per day.
During the active treatment period patients were seen every 12
weeks. Renal function studies were performed at baseline, after
the 12-week titration period, and each subsequent 24 weeks
during the follow-up of four years (204 weeks). Altogether, nine
renal hemodynamic studies were carried out during the active
treatment (at week 12, 36, 60, 84, 108, 132 and 156, 180, 204). At
week 204 the antihypertensive treatment was withdrawn and renal
function studies were repeated 12 weekt after treatment with-
drawal.
Overall, 40 patients (21 male, 19 female) with a mean age of
49.3 11.8 years were included. The cause of the renal disease
was hypertensive nephrosclerosis in 14, urological abnormalities
with chronic pyelo-interstitial nephritis in 12, chronic glomerular
diseases (not requiring immunosuppressive therapy) in 5, polycys-
tic kidney disease in 5, and unknown in 4 patients.
Methods
Blood pressure and heart rate were recorded with a noninvasive
automated device (Dinamap®) after 10 minutes of supine rest.
The mean of five recordings was used. The values registered for
diastolic blood pressure were those corresponding to Korolkoff
phase V. Mean arterial pressure (MAP) was calculated as the sum
of diastolic blood pressure and one third of pulse pressure. GFR
and ERPF were measured as the clearance of constantly infused
125l-iothalamate and '311-hippuran, respectively [7]. The day-to-
day coefficient of variation of this method is 2.2% and 5.0%,
respectively. Filtration fraction (FF) is given as the ratio of GFR
and ERPF. Progression of renal disease was estimated for each
individual by calculating the slope of the nine GFR measurements
obtained while on active treatment plotted versus time by linear
regression analysis. To assess the true treatment-induced change
in GFR as well as the true treatment withdrawal effect, the initial
and withdrawal GFR changes were corrected for any underlying
long-term GFR change.
Results are presented as mean SD values. Treatment effects
were analyzed using the paired samples Student's t-test. To test
for differences between subgroups a two sample f-test was used.
Correlations were calculated using regression analysis. Statistical
significance was assumed at a P value of less than 5%.
Results
The course of the study parameters at the start of the treatment
(from weeks 0 to 12) and after treatment withdrawal (from weeks
204 to 216) are shown in Table 1. Blood pressure fell after start of
treatment, remained stable during the four years of follow-up, and
increased after treatment withdrawal to the pre-treatment values.
After start of treatment the change in GFR showed a wide
variation, ranging from —11 to +11 mi/mm, with a mean fall of
—1.0 4.1 mi/mm (NS). During the four years of follow-up a slow
but steady decrease occurred, with a mean slope of —1.25 2.37
ml/min/year (P < 0.001, range + 1.91 to —10.73 ml/min!year). No
significant correlation was found between the slope of GFR and
baseline characteristics, such as age (r =
—0.09, NS), GFR (r =
—0.03, NS), systolic (r = —0.257, NS) and diastolic (r = —0.18,
NS) blood pressure and proteinuria (r = —0.26, NS). After
treatment withdrawal GFR increased by 2.2 5.4 ml/min (P =
0.011, range +14 to —6 mI/mm). The initial fall in GFR correlated
with the rise in GFR after treatment withdrawal (r =
—0.32, P <
0.05). Since the initial change in GFR, besides being treatment-
induced, could also be the result of the underlying continuing
GFR change, we corrected the initial GFR change for the
following slope. Corrected initial GFR fell by —1.7 4.1 mI/mm
(P = 0.015, range from —13.8 to + 10.2 ml/min). This GFR fall
was related to the long-term slope, such that a patient with a
greater initial fall in GFR showed a more stable course during
follow-up (r —0.36, P < 0.05; Fig. I). The correlation between
the initial fall in FF and in MAP with the long-term GFR decline
did not reach statistical significance (r 0.10 and r 0.22,
respectively). The rise in corrected GFR after treatment with-
drawal was 2.9 4.9 ml/min (P 0.001, range from + 15.2 to —5.2
mI/mm). Similarly, FF fell at baseline (P < 0.001) and increased
after withdrawal of treatment (P = 0.001).
To further evaluate the effect of the acute GFR change on the
follow-up parameters, we divided the 40 patients in a group with
a distinct initial fall in GFR (group A, 20 patients) and a group
with initially a stable GFR (group B, 20 patients). The baseline
characteristics in these two subgroups are given in Table 2. No
statistically significant differences were present between the two
subgroups, although blood pressure tended to be higher in group
A, and proteinuria tended to be higher in group B. In group B
male sex predominated and less patients with nephrosclerosis hut
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Fig. 1. Initial change in GFR plotted against long-term slope. Symbols are:(•) 20 patients who showed a distinct initial decline in GFR (group A);
(0) 20 patients in whom no decline or even a rise in GFR occurred after
starting antihypertensive therapy (group B).
more with polycystic kidney disease were present. The fall in
blood pressure after start of treatment was not different between
the group A and B patients (Table 3). The fall in GFR was by
definition different between both groups (P < 0.00 1). Whereas the
fall in GFR in group A was associated with a fall in FF (P =
0.008), GFR in group B increased without a significant change in
FF. Similarly, the rise in blood pressure after withdrawal of
treatment was comparable between the two groups. The change in
GFR after treatment withdrawal was more pronounced in group
A as compared to group B (P = 0.045): GFR and FF increased in
group A (P = 0.007 and P = 0.001, respectively), whereas it did
not change in group B. The absolute data of GFR at all time
points and the slope of the group A and B patients is given in
Figure 2. The slope of the group A patients (—0.41 1.52
ml/min/year), in whom GFR initially had fallen (result of the
selection), was less steep than the slope of the group B patients
(—2.09 2.79 mI/mm/year, P = 0.023), that initially had not
shown a fall in GFR. Due to the rise in GFR after treatment
withdrawal in group A the GFR post-treatment was not signifi-
cantly different as compared to pre-treatment (—2.5 7.2 mI/mm,
NS), whereas GFR in group B was significantly lower post-
treatment than pre-treatment (—5.9 12.1, P = 0.023). Thus, in
the group that initially had shown a fall in GFR, GFR was clearly
more stable in the long run. Interestingly, the number of patients
allocated to both treatment modalities (ACE inhibitor or beta-
blocker) was comparable in group A and B (8 out of the 20
patients in group A and 12 out of the 20 patients in group B used
an ACE inhibitor). Moreover, the initial change in MAP
(—17.2 7.2 vs. —18.4 9.6 mm Hg), GFR (—0.7 4.2 vs.
—1.3 3.9 mI/mm) and FF (—0.018 0.021 vs. —0.017 0.029)
and the slope of GFR (—1.36 2.75 vs. —1.14 1.81) were not
different between the enalapril and the atenolol treated patients.
The number of patients that needed additional antihypertensive
treatment was similar in group A and B: in both groups three
patients needed diuretics alone and two other patients needed
diuretics and another antihypertensive medication.
Discussion
This study shows that the initial change in GFR after the start
of antihypertensive therapy with either an ACE inhibitor or a beta
Group A Group B
N 20 20
Age years 51.9 8.3 46.7 13.9
Sex 8m, 12f 13m, 7f
Serum creatinine pinol/liter 152.4 44.1 158.2 49.5
GFR mI/mm 55.6 21.8 56.1 22.9
ERPF mI/mm 216.2 81.0 210.6 83.5
FF 0.261 0.047 0.270 0.039
Proteinuria g/day 0.44 0.72 1.38 2.03
SBP mm Hg 156.2 23.2 152.3 20.3
DBP 92.3 12.2 89.9 13.1
MAP 113.6 15.3 110.7 13.6
Diagnosis
Nephrosclerosis 10 4
Urological abnormalities 5 7
Glomerular diseases 3 2
PCKD 0 5
Unknown 2 2
Concommittant antihypertensives
Diuretics 3 3
Others 2 2
blocking agent is highly variable, and if present, reversible even
after years of treatment. This reversibility indicates that the
treatment-induced initial changes are of hemodynamic and not of
structural origin. To our knowledge this is the first time this
reversibility of initial changes after long-term follow-up has been
reported in non-diabetic renal disease. Interestingly, this initial
fall in GFR appears to be related to the subsequent slope such
that a great initial fall in GFR is followed by a relatively stable
slope, whereas the absence of an initial change in GFR after start
of antihypertensive treatment is followed by a progressive decline
in GFR during follow up.
To further study the cause of this relation we first analyzed the
baseline characteristics of the patients who showed progression
and those that showed stable renal function on the long-term. It
could be that differences in blood pressure [8] or in proteinuria [9]
could account for a more severe progression of their renal disease.
To test this hypothesis, the patients were divided into two groups
on the basis of their initial GFR fall. The group with the largest
initial GFR fall had a stable long-term GFR slope whereas the the
group with no initial change in GFR upon antihypertensive
treatment showed a progressive GFR decline during follow up.
The difference in long-term slope could however, not be fully
explained by any of the baseline parameters. Baseline blood
pressure even tended to be lower in the patients with a progressive
fall in GFR in the long run, whereas baseline proteinuria tended
to be somewhat higher in that group. One should realize, how-
ever, that both blood pressure and proteinuria were lower during
follow-up. Indeed, both blood pressure and proteinuria were
equally well treated in both subgroups. It could still be true that
the patients with initially a greater fall in GFR are less able to
autoregulate, so that the early decrease in pressure is associated
with a greater fall in GFR and that the subsequent slower
progression is due to the good control of blood pressure. A second
explanation for a difference in slope between the patient groups
4
2
-400
(I)
Lj -8
a
—10
0.0.: 000
.1 % 00
0 0
00
Table 2. Baseline parameters in the two subgroups
Abbreviations are: SBP, systolic blood pressure; DBP, diastolic blood
pressure; MAP, mean arterial pressure; GFR, glomerular filtration rate;
ERPF, effective renal plasma flow; FF, filtration fraction; Prot, protein-
uria; PCKD polycystic kidney disease. No statistically significant differ-
ences were present between group A and B.
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Table 3. Changes in the study parameters in the group A and group B patients after start of treatment and after treatment withdrawal
SBP mm Hg
Start treatment Treatment withdrawal
Group A Group B Group A Group B
—26.4 14.0" —21.2 10.6" +23.4 14.7" +25.2 14.4"
DBP mm Hg —15.8 8.3 —13.9 5.4" +15.4 7.9" +14.9 7.6"
MAP mm Hg —19.3 9.8" —16.3 6.5" +18.1 9.8" +18.3 9.1"
GFR mi/mm —3.7 3.0" +1.7 3.0"" +3.8 5.6" +0.5 4.0"
ERPF mI/mm +4.9 25.2 + 15.7 18.0" +2.3 37.3 —7.8 19.1
FF —0.025 it 0.026" —0.010 0.022" +0.028 0032h +0.010 0.033"
Protg/day —0.26 0.50" —0.49 0.80" +0.69 l.l0" +0.90 0.89"
Abbreviations are: SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; GFR, glomerular filtration rate; ERPF,
effective renal plasma flow; FF, filtration fraction; Prot, proteinuria.
Significance is indicated by "compared to pre-treatment value, by "compared to last treatment value, and by "compared to group A change.
0 50 100 150 200
Time, weeks
Fig.2. Time course of GFR before, during and after withdrawal of antihy-
pertensive treatment in group A and group B. Group A (•) are patients who
initially showed a distinct fall in GFR and group B (0) are patients in
whom GFR did not fall after start of treatment. The change in GFR after
start and withdrawal of treatment is indicated as well as the slope of GFR
during treatment.
could be the gender or the underlying renal disease. A slight
preponderance for the male sex and for the diagnosis of polycystic
kidney disease was found in the poor prognosis group. Both sex
[10, 11] and diagnosis [4, 9, 11 are reported to influence renal
prognosis, although polycystic kidney disease has been argued to
be related to either a worse [4] or a better [11] renal function
outcome. However, even if the above baseline characteristics
explain the difference between the patient groups in progression
of GFR, it still remains to be explained why the initial GFR
response to antihypertensive treatment is so different between
progressors and non-progressors,
The observed relation between the initial renal hemodynamie
response and the subsequent slope of GFR could just he a
regression to the mean phenomenon. However, the fact that the
GFR fall was reversible after years of treatment makes this bias
unlikely. Alternatively, a patient on a steep slope of GFR loss and
an impaired GFR could for physiological reasons just have
responded less upon initial treatment. However, this seems un-
likely since the initial GFR response occurred both in patients
with a lower GFR and in patients with a less impaired GFR.
How then can we interpret the relationship between the initial
response and the final outcome? It could well fit the hypothesis
that an initial fall in GFR represents a fall in intraglomerular
pressure. Such a fall in intraglomerular pressure in animal models
has been found to prevent progressive renal disease and glomer-
uloscierosis [6, 12—14]. Certainly, a fall in GFR together with a fall
in FF, as we observed in the group A patients, would support such
a decrease in intraglomerular pressure. Although group B but not
group A patients showed a rise in ERPF, this rise in ERPF was in
the group B patients associated with a rise in GFR, whereas in
group A patients GFR fell and consequently also FF fell. This
suggests that an efferent vasodilation was achieved only in the
group A patients. If so, a marked initial fall in GFR may indeed
reflect the adequacy of the renal protective therapy, and thus
explain the less steep, long-term slope compared to the more
negative slope in an individual in whom initial GFR did not fall
upon therapy. A similar observation has recently also been made
by Hansen et at, who studied the effects of antihypertensive
treatment on long-term renal function in diabetic patients [5].
Unfortunately, both our study and that of Hansen et al have no
data on the slope of GFR before treatment to verify that the
hypothesis holds true. In support, however, are the data of other
intervention studies in which an initial GFR fall occurs in the
active and renal protected treatment group whereas the control
group does not show this initial GFR fall [3, I.
Interestingly, the long-term slope of GFR was not different
between the enalapril and atenolol treated patients, whereas ACE
inhibitors are claimed to be renal protective compared to beta
blocking drugs [15, 16]. First of all, one should realize that this
study in a small group of patients was underpowered to detect a
difference between both drug regimens. Interestingly, the initial
systemic and renal hemodynamic response were not different
between the two treatment groups. In both groups a comparable
change in CJFR and in filtration fraction was observed, suggesting
that in both groups a fall in intraglomerular capillary pressure had
occurred in parallel with a marked fall in systemic blood pressure.
Rcnoprotection may thus not solely he related to the type of
treatment, but more to whether a certain medication is able to
lower intraglomerular pressure in the individual patient. In this
respect also it is of interest that in the Collaborative Group Study
by Lewis et al, no difference was noted between those diabetics
who received captopril and those who did not when the MAP was
below 95 mm Hg (unpublished data).
What can be learned from our data? First, initial, more
pronounced fall in GFR after the start of treatment is not an
ominous, hut in contrast an encouraging finding, since it may
indicate that renal function in the tong-term may remain stable
during that treatment. One should start worrying about the course
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of renal function when during the beginning period of a given
treatment no GFR fall or even a rise in GFR occurs. Second, our
observations have important implications for the analysis of renal
function intervention trials. In the final analysis of such studies it
is still debated whether the pre-treatment GFR measurement
should be included in long-term slope calculations. Inclusion of
the baseline datapoint in case of an initial GFR decline causes the
slope to be more steep. Our results argue for omitting this
baseline GFR value in the slope calculations, since the initial
decline is fully reversible after withdrawal of treatment.
In conclusion, an initial fall in GFR occurring after starting
antihypertensive treatment in patients with a mild to moderate
renal function impairment is associated with less renal function
loss during continued treatment. This initial fall is reversible after
long-term treatment. As such, the therapy-induced GFR fall may
well reflect a renal hemodynamic change that predicts a beneficial
effect of long-term treatment.
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